{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:39:37Z","timestamp":1787031577109,"version":"build-2736575974"},"reference-count":31,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease significantly impacting patients\u2019 quality of life (QoL) and necessitating complex, long-term treatment. This study aimed to assess the long-term therapeutic outcomes of biologic therapies in a real-world clinical setting, focusing on the achievement and maintenance of low disease activity (LDA) among RA patients, while also investigating factors influencing these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>A retrospective observational analysis was conducted on 190 RA patients receiving tumor necrosis factor \u03b1 (TNF-\u03b1) or interleukin (IL)-6 inhibitors. Disease activity was evaluated using the Disease Activity Score 28 (DAS28) at baseline, 6 months, and 12 months. Based on the DAS28 with C-reactive protein (DAS28-CRP) values, the disease was categorized into 2 main groups: remission\/low activity (target achieved) when the DAS28-CRP value was less than 3.2, and insufficient therapeutic response when the value exceeded 3.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study group consisted of 190 RA patients, predominantly women (85.8%), with a mean age of 58.7 years and a disease duration of 12.5 years. We found that 45.8% of patients achieved single-point LDA, with 39.5% sustaining this response after 12 months. Notably, comorbidities such as diabetes and smoking negatively affected the likelihood of maintaining LDA. Statistical analysis revealed that patients without diabetes had a significantly higher chance of retaining sustained LDA (OR = 0.100; p = 0.014).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings emphasize the need for personalized treatment approaches that consider comorbidities and lifestyle factors to enhance long-term therapeutic efficacy in RA management. Consequently, this study highlights the critical importance of ongoing monitoring and indivi\u00addualized strategies to improve outcomes and QoL for patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/reum\/199933","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:42:51Z","timestamp":1744616571000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of comorbidities, diabetes, and smoking on sustained \noutcomes in rheumatoid arthritis: a retrospective study"],"prefix":"10.5114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9309-236X","authenticated-orcid":false,"given":"Zhaklin","family":"Apostolova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-4100","authenticated-orcid":true,"given":"Tanya","family":"Shivacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetoslav","family":"Georgiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"ref-1424167","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"ref-1424168","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.77973"},{"key":"ref-1424170","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2020.98432"},{"key":"ref-1424173","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1403"},{"key":"ref-1424175","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090174"},{"key":"ref-1424177","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01946-w"},{"key":"ref-1424179","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.12.006"},{"key":"ref-1424181","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.05.044"},{"key":"ref-1424183","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204223"},{"key":"ref-1424188","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.102017"},{"key":"ref-1424190","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75673-7"},{"key":"ref-1424192","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"ref-1424194","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"ref-1424196","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237179"},{"key":"ref-1424198","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"ref-1424200","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22678"},{"key":"ref-1424204","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207080"},{"key":"ref-1424209","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070856"},{"key":"ref-1424210","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-"},{"key":"ref-1424212","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05853-x"},{"key":"ref-1424214","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141575"},{"key":"ref-1424216","doi-asserted-by":"publisher","DOI":"10.1002\/art.41720"},{"key":"ref-1424218","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56040178"},{"key":"ref-1424220","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06307-8"},{"key":"ref-1424223","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00189-0"},{"key":"ref-1424226","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010048"},{"key":"ref-1424228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00589"},{"key":"ref-1424230","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/764518"},{"key":"ref-1424231","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22249"},{"key":"ref-1424236","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06656-y"},{"key":"ref-1424238","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05453-9"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-199933-124455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-199933-124455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:42:51Z","timestamp":1744616571000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Impact-of-comorbidities-diabetes-and-smoking-on-sustained-noutcomes-in-rheumatoid,199933,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":31,"alternative-id":["199933"],"URL":"https:\/\/doi.org\/10.5114\/reum\/199933","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}